There is a growing demand for generic drugs in Malaysia. The government is the largest pharmaceutical buyer in Malaysia and is responsible for more than half of the purchasing value. The Indian, Chinese, and other similar drug manufacturers have begun playing a dominant role in the Malaysian pharmaceutical market. Note: This article was updated in […]

Read More →

The demand for healthcare products and services has been growing in ASEAN countries. Governments start facing the same problem as in more developed countries and struggle to finance the growing healthcare expenses. There is a steep increase in chronic diseases along with infectious diseases. This is creating an opportunity for the generic drug manufacturers to […]

Read More →

In 2019, the global generic drugs market reached a value of US$ 367 Billion. with a CAGR of 5.7% during the period 2014-2019. The US generic drug market is foreseen to reach US$ 208.6 Billion by 2025, with a projected CAGR of 10.46% during 2020-2025, according to a report by IMARC Group,  The global biosimilars […]

Read More →

Cost and time for clinical development constitute more than 70% of the total development of any drug! Small – mid-scale biopharma are known for their innovative approaches, agility, and faster developments. However, clinical development has always been one step too important, yet too hard for them. There are ways to overcome these challenges and optimize […]

Read More →